ACM
REGN icon

AlphaCrest Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

AlphaCrest Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,822
Closed -$1.25M – 900
2022
Q3 		$1.25M Sell
1,822
-3,230
-64% -$2.03M 0.08% 471
2022
Q2 		$2.99M Buy
5,052
+1,077
+27% +$700K 0.14% 167
2022
Q1 		$2.78M Sell
3,975
-3,800
-49% -$2.4M 0.16% 140
2021
Q4 		$4.91M Buy
7,775
+105
+1% +$64.6K 0.18% 98
2021
Q3 		$4.64M Buy
7,670
+958
+14% +$595K 0.24% 69
2021
Q2 		$3.75M Sell
6,712
-433
-6% -$219K 0.16% 173
2021
Q1 		$3.38M Buy
7,145
+3,159
+79% +$1.54M 0.19% 126
2020
Q4 		$1.93M Buy
3,986
+2,272
+133% +$1.23M 0.16% 141
2020
Q3 		$959K Buy
1,714
+873
+104% +$529K 0.1% 271
2020
Q2 		$524K Sell
841
-84
-9% -$47.7K 0.09% 369
2020
Q1 		$452K Sell
925
-644
-41% -$266K 0.05% 616
2019
Q4 		$589K Sell
1,569
-12,764
-89% -$4.29M 0.05% 681
2019
Q3 		$3.98M Buy
14,333
+9,163
+177% +$2.71M 0.24% 59
2019
Q2 		$1.62M Buy
+5,170
New +$1.72M 0.14% 211

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCrest Capital Management's REGN Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 1,822 shares — an estimated $1.25M sold.

AlphaCrest Capital Management first reported a position in REGN in Q2 2019 and held it in 14 quarters. The position peaked at $4.91M in Q4 2021. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 1,822 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $1.25M.
  • AlphaCrest Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 14 quarters.
  • AlphaCrest Capital Management's Regeneron Pharmaceuticals position peaked at $4.91M in Q4 2021.
  • 1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.